TY -的T1 -包含bedaquiline方案和delamanid相比,耐药结核病患者bedaquiline JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01181 -2019欧元六世- 55 - 1 SP - 1901181 AU Olayanju Olatunde盟——提出Aliasgar AU - Limberis,杰森盟——DhedaKeertan Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/55/1/1901181.abstract N2 -在耐药结核病(DR-TB)方案中联合使用delamanid和bedaquiline的数据有限。目前还没有预期的长期结果数据，包括艾滋病毒感染者的数据。2014年至2018年，我们前瞻性随访了122名南非患者(52.5%的艾滋病毒感染)，这些患者均患有耐药结核病，预后较差。我们比较了接受bedaquiline-based方案(n=82)和接受bedaquiline-delamanid联合方案(n=40)的结果和安全性。6个月培养转化率无显著差异(92.5% vs 81.8%;P =0.26)和18个月预后良好率(63.4% vs 67.5%;P =0.66)，尽管后者对至少5种药物的耐药程度更高(3.7% vs 22.5%;p=0.001)和更高的治疗前失败率(12.2% vs 52.5%，治疗前多药耐药结核病治疗失败;术中,0.001)。尽管联合治疗组使用弗里德里西亚公式纠正的QT间期延长的比例更高(与基线相比60 ms (p=0.001)或治疗期间450 ms (p=0.001))，但两组均无症状病例或停药。 Results were similar in HIV-infected patients.A bedaquiline–delamanid combination regimen showed comparable long-term safety compared to a bedaquiline-based regimen in patients with DR-TB, irrespective of HIV status. These data inform regimen selection in patients with DR-TB from TB-endemic settings.A bedaquiline–delamanid combination regimen in drug-resistant tuberculosis patients with poor prognostic factors showed comparable efficacy and safety to those in a bedaquiline-based regimen http://bit.ly/32j7Fyo ER -